NGM Biopharmaceuticals (NGM) – Company Press Releases
-
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
-
NGM Bio to Participate in Upcoming Investor Conferences
-
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Ma
-
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
-
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
-
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
-
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
-
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
-
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
-
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
-
Belharra Therapeutics Debuts With $130 Million in Funding
-
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
-
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
-
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
-
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
-
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
-
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
-
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
-
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
-
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Soc
-
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Soc
-
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
-
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
-
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
-
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
-
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors
-
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors
-
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology
-
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
-
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
-
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
-
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
-
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
-
NGM Bio to Participate in Upcoming Investor Conferences
-
NGM Bio to Participate in Upcoming Investor Conferences
-
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
-
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
-
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
-
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
-
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
-
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
-
NGM Bio to Participate in Upcoming Investor Conferences
Back to NGM Stock Lookup
